test

Neuroblastoma Antibody Study

Conditions

Brain and Nervous System | Disseminated Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma

Trial Phase

Phase III

Trial Purpose and Description

Trial Purpose

This study is for a continuing treatment for high risk neuroblastoma. This study is called a clinical trial. A clinical trial is a research study involving treatment of a disease in human patients. This study is organized by Children’s Oncology Group (COG). COG is an international research group that conducts clinical trials for children with cancer. More than 200 hospitals in North America, Australia, New Zealand, and Europe are members of COG. It is common to enroll children and adolescents with cancer in a clinical trial that seeks to improve cancer treatment over time. Clinical trials include only people who choose to take part.


Participation Guidelines

Age:
Up to 30 Years
Gender:
Both

Eligibility Criteria

Inclusion Criteria:

  • Diagnosis of neuroblastoma
  • Categorized as high risk at diagnosis exception: patients who are initially
    diagnosed as non-high-risk neuroblastoma, but later converted (and/ or relapsed)
    to high risk neuroblastoma are also eligible
  • Meets all of the following criteria:
  • Patients must have completed therapy including intensive induction followed by
    autologous stem cell transplantation (ASCT) and radiotherapy
  • Radiotherapy may be waived for patients who either have small adrenal
    masses which are completely resected up front, or who never have an
    identifiable primary tumor
  • Completed frontline therapies, examples of such therapy includes:
    • Following treatment per COG-A3973 protocol
    • Following treatment per POG-9340-42
    • Following treatment per CCG-3891
    • Following treatment on NANT-2001-02
    • Enrollment on or following treatment per COG-ANBL02P1 protocol
    • Enrollment on or following treatment per ANBL07P1
    • Tandem transplant patients are eligible
    • Following enrollment and treatment on or per COG-ANBL0532
    • Following treatment per POG-9640 protocol
    • Following treatment per COG-ANBL00P1 protocol
    • Following treatment per CHP 594 or DFCI 34-DAT
    • Other frontline therapy with permission from study chairs
  • Must meet the International Neuroblastoma Response Criteria (INRC)for CR, VGPR, or PR
    for primary site, soft tissue metastases, and bone metastases AND must also meet the
    protocol specified criteria for bone marrow response as follows:
  • No more than 10% tumor (of total nucleated cellular content) seen on any
    specimen from a bilateral bone marrow aspirate/biopsy
  • Patient who have no tumor seen on the prior bone marrow, and then have = 10%
    tumor on any of the bilateral marrow aspirate/biopsy specimens done at pre-ASCT
    and/or pre-enrollment evaluation will also be eligible
  • No more than 12 months from the date of starting the first induction chemotherapy
    after diagnosis to the date of ASCT except for the rare occasions as noted below for
    tandem ASCT patients, this will be the date of the FIRST stem cell infusion
    exception: For those who are initially diagnosed as non-high risk neuroblastoma, but
    later converted (and/or relapsed) to high risk neuroblastoma, the 12 months
    restriction should start from the date of induction therapy for high risk
    neuroblastoma (not from the initial induction therapy for non-high risk disease), to
    the date of ASCT
  • Prior to enrollment on ANBL0032, a determination of mandatory disease staging must be
    performed (tumor imaging studies including CT or MRI, MIBG scan, bone marrow
    aspiration & biopsy) this disease assessment is required for eligibility and should
    be done preferably within 2 weeks, but must be done within a maximum of 4 weeks
    before enrollment
  • For those with residual disease before radiotherapy, re-evaluation of irradiated
    residual tumors is preferably performed at the earliest 5 days after completing
    radiotherapy patients with residual disease are eligible biopsy is not
    required patients who have biopsy proven residual disease after ASCT will be
    enrolled on Stratum 07
  • Patients must not have progressive disease at the time of study enrollment
    except for protocol specified bone marrow response these patients will be
    enrolled on Stratum 07
  • Performance status - Lansky 50-100%
  • Performance status - Karnofsky 50-100%
  • Total absolute phagocyte count (neutrophils and monocytes) = 1,000/mm^3
  • Bilirubin = 1.5 times normal
  • SGPT = 5 times normal
  • Veno-occlusive disease (if present) stable or improving
  • Creatinine adjusted according to age as follows:
    • No greater than 0.4 mg/dL (= 5 months)
    • No greater than 0.5 mg/dL (6 months - 11 months)
    • No greater than 0.6 mg/dL (1 year- 23 months)
    • No greater than 0.8 mg/dL (2 years- 5 years)
    • No greater than 1.0 mg/dL (6 years- 9 years)
    • No greater than 1.2 mg/dL (10 years- 12 years)
    • No greater than 1.4 mg/dL (13 years and over [female])
    • No greater than 1.5 mg/dL (13 years to 15 years [male])
    • No greater than 1.7 mg/dL (16 years and over [male])
  • Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min
  • Shortening fraction = 30% by echocardiogram, or if shortening fraction abnormal,
    ejection fraction of >= 55% by gated radionuclide study or echocardiogram
    • Note: The echocardiogram or gated radionuclide study must be performed within 4
      weeks prior to enrollment
  • FEV1 and FVC > 60% predicted by pulmonary function test for children who are unable
    to do PFTs, no evidence of dyspnea at rest and no exercise intolerance should be
    documented
    • Note: The pulmonary function test must be performed within 4 weeks prior to
      enrollment
  • No evidence of dyspnea at rest, no exercise intolerance
  • Not pregnant
  • Fertile patients must use effective contraception
  • Seizure disorder allowed if well-controlled and on anticonvulsants
  • CNS toxicity < grade 2
  • No concurrent pentoxifylline
  • No more than 1 prior stem cell transplantation
  • No other concurrent cytokines or growth factors (e.g., filgrastim [G-CSF] or
    interferon)
  • No IV immunoglobulin G within 2 weeks before, during, and for 1 week after monoclonal
    antibody Ch14.18 (arm II patients)
  • Patients must be enrolled before treatment begins the date protocol therapy is
    projected to start must be no later than ten (10) calendar days after the date of
    study enrollment
  • Patients should be enrolled preferably between Day 56 and Day 85 after PBSC
    infusion (day from 2nd stem cell infusion for tandem transplant) patients must
    be enrolled no later than Day 100 after PBSC infusion enrollment must occur
    after completion of radiotherapy, and after completion of tumor assessment
    post-ASCT and radiotherapy informed consent should be obtained within 3 weeks
    pre-ASCT up to the time of registration
  • All clinical and laboratory studies for organ functions to determine eligibility
    must be performed within 7 days prior to enrollment unless otherwise indicated
  • No prior anti-GD2 antibody therapy
  • No more than 1 prior myeloablative consolidation regimen
  • No concurrent myelosuppressive chemotherapy (arm II patients)
  • No concurrent corticosteroids unless for life-threatening conditions (e.g., increased
    intracranial pressure from CNS tumors or life-threatening allergic reactions)
  • No radiographic contrast materials during and for at least 1 week after interleukin-
    2 (arm II)
  • At least 7 days since prior radiotherapy
  • No other concurrent anticancer therapy
  • No concurrent immunosuppressive drugs (e.g., cyclosporine)
Sponsor:
Children's Oncology Group (The)
 
National Cancer Institute (NCI)
Dates:
11/08/2011
Last Updated:
Study HIC#:
1110009218